Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amneal Aims To Expand Internationally

As Firm Lines Up Pipeline And Develops Biosimilars Business

Executive Summary

Amneal has laid out ambitious plans for 2020 to deliver value and volume growth, including by expanding internationally, augmenting organic growth through M&A and capitalizing on its pipeline of ANDAs and development projects. The firm will seek to build on its launch of 38 products in 2019 as well as benefiting from recent key appointments to its board.

You may also be interested in...



Who’s Hired? George and Yanai Join Amneal’s Board

Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.

Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel